For the quarter ended September 2025, Royalty Pharma (RPRX Quick QuoteRPRX - Free Report) reported revenue of $814 million, up 10.8% over the same period last year. EPS came in at $1.17, compared to $1.04 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $803.28 million, representing a surprise of +1.34%. The company delivered an EPS surprise of +5.41%, with the consensus EPS estimate being $1.11.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Royalty Pharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise: $222 million versus the two-analyst average estimate of $217.58 million. The reported number represents a year-over-year change of +7.3%.
• Portfolio Receipts- Royalty Receipts- Products- Tysabri: $68 million versus the two-analyst average estimate of $66.97 million. The reported number represents a year-over-year change of -0.4%.
• Portfolio Receipts- Royalty Receipts- Products- Imbruvica: $41 million compared to the $42.6 million average estimate based on two analysts. The reported number represents a change of -11.3% year over year.
• Portfolio Receipts- Royalty Receipts- Products- Xtandi: $50 million versus the two-analyst average estimate of $47.09 million. The reported number represents a year-over-year change of +15.4%.
• Portfolio Receipts- Royalty Receipts- Products- Promacta: $38 million versus $37.43 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -9.1% change.
• Portfolio Receipts- Royalty Receipts- Products- Spinraza: $14 million versus the two-analyst average estimate of $11.78 million. The reported number represents a year-over-year change of 0%.
• Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq: $21 million versus the two-analyst average estimate of $21.84 million. The reported number represents a year-over-year change of +13.4%.
• Portfolio Receipts- Royalty Receipts- Products- Evrysdi: $52 million versus the two-analyst average estimate of $50.52 million. The reported number represents a year-over-year change of +8.4%.
• Portfolio Receipts- Royalty Receipts- Products- Trodelvy: $12 million versus the two-analyst average estimate of $12.68 million. The reported number represents a year-over-year change of +4.6%.
• Portfolio Receipts- Royalty Receipts- Products- Total: $811 million versus the two-analyst average estimate of $799.38 million. The reported number represents a year-over-year change of +10.8%.
• Portfolio Receipts- Royalty Receipts- Products- Trelegy: $96 million versus the two-analyst average estimate of $94.06 million. The reported number represents a year-over-year change of +6%.
• Portfolio Receipts- Royalty Receipts- Products- Tremfya: $49 million compared to the $47.47 million average estimate based on two analysts. The reported number represents a change of +43% year over year.

View all Key Company Metrics for Royalty Pharma here>>>

Shares of Royalty Pharma have returned +4.8% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.